Conditions · Alzheimer's disease & early-stage dementia
Alzheimer's disease & early-stage dementia — frontier options in Florida
Prefer to look first? Browse the live map without signing up.
30 open options
- TRIALPHASE3RECRUITING
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
KarXT — 429 sites
- TRIALPHASE3RECRUITING
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Acoramidis · Placebo oral tablet — 104 sites
- TRIALPHASE2RECRUITING
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
Donanemab · Placebo — 72 sites
- TRIALNANOT_YET_RECRUITING
Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 2
Project 2, Phase 2: Intelligent Adaptive System — 3 sites
- TRIALNAENROLLING_BY_INVITATION
Software Validation Study-Cognitive Status Indicator
SPARK Cognitive Status Indicator (software support data collected via EEG) — 1 site
- TRIALPHASE2RECRUITING
Open-label Extension Study in Participants With Early Alzheimer's Disease
GSK4527226 — 33 sites
- TRIALPHASE2ENROLLING_BY_INVITATION
Neuroimaging Study
Tau PET scan — 2 sites
- TRIALNANOT_YET_RECRUITING
Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 1
Project 1 - Phase 2: VR Program for Social, Activity, and Cognitive Engagement · Project 1 - Phase 2: Tablet for Social, Activity, and Cognitive Engagement — 3 sites
- TRIALPHASE2ENROLLING_BY_INVITATION
An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
ML-007C-MA — 8 sites
- TRIALPHASE2RECRUITING
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
ML-007C-MA · Placebo — 55 sites
- TRIALPHASE1RECRUITING
A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration
BMS-986446 — 6 sites
- TRIALNARECRUITING
The Active Mind Trial: An Adaptive Randomized Trial to Improve Function and Delay Dementia
Cognitive Training · Computerized Cognitive Stimulation — 6 sites
- TRIALPHASE2RECRUITING
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
VHB937 · VHB937 · Placebo — 74 sites
- TRIALPHASE3RECRUITING
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
Donanemab · Placebo — 59 sites
- TRIALPHASE3ENROLLING_BY_INVITATION
ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
ACP-204 — 76 sites
- TRIALPHASE3RECRUITING
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
KarXT · KarX-EC · Placebo — 119 sites
- TRIALPHASE2RECRUITING
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
MK-2214 · Placebo — 80 sites
- TRIALEARLY_PHASE1RECRUITING
LpD3.5 Intervention Study in Older Adults- LISA-I Trial
LpD3.5 · Placebo — 1 site
- TRIALNARECRUITING
Personalized Obstructive Sleep Apnea Treatment and Effects on Alzheimer's Disease Biomarkers and Cognition Among Blacks
Standard of Care · Personalized OSA Treatment — 1 site
- TRIALPHASE1NOT_YET_RECRUITING
A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)
LY4560736 · LY4560736 · Placebo — 16 sites
- TRIALNARECRUITING
Anxiety Sensitivity Treatment to Reduce Anxiety in Alzheimer's
Computerized Anxiety Sensitivity Treatment · Health Education Control — 3 sites
- TRIALPHASE3RECRUITING
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
KarXT · Placebo — 296 sites
- TRIALPHASE1RECRUITING
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
LY4006895 · Placebo — 13 sites
- TRIALNARECRUITING
Pulsed Electromagnetic Field Treatment With Dementia Patients
ECHS AD Device — 1 site
- TRIALNANOT_YET_RECRUITING
Probiotic Milk Drink for Gut and Brain Health in Older Adults and Caregivers
Probiotic Fermented Milk (PFM) Drink · Placebo — 1 site
- TRIALPHASE2RECRUITING
Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.
hMSC — 1 site
- TRIALPHASE3RECRUITING
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
KarXT · KarX-EC · KarXT + KarX-EC Arm Matching Placebo — 22 sites
- TRIALPHASE3RECRUITING
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
No Intervention — 229 sites
- TRIALPHASE3RECRUITING
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
Trontinemab · Placebo — 7 sites
- TRIALPHASE2RECRUITING
Cognitive Training and Neuroplasticity in Mild Cognitive Impairment: COGIT-2 Trial
Cognitive Training — 4 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.